Cargando…
Efficacy and Safety of Orally Administered Acotiamide Extended-Release Tablets Among Functional Dyspepsia-Postprandial Distress Syndrome Patients: A Randomized, Double-Blind, Multicenter Study
Background: Acotiamide, is the world's first-in-class, prokinetic drug and world’s first approved treatment for postprandial distress syndrome (PDS) symptoms of functional dyspepsia (FD). An extended-release (ER) formulation of this drug product, developed first-time in the world has been evalu...
Autores principales: | Sinha, Shubhadeep D, Sinha, Saroj K, Talluri, Leela, Bhashyakarla, Ramesh K, Malladi, Umadevi, Dosi, Rupal V, Jain, Mukesh K, Chary, Sreenivasa, Reddy, Mohan, Thakur, Pankaj |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8098008/ https://www.ncbi.nlm.nih.gov/pubmed/33968542 http://dx.doi.org/10.7759/cureus.14361 |
Ejemplares similares
-
Efficacy and Safety of Acotiamide Versus Mosapride in Patients With Functional Dyspepsia Associated With Meal-Induced Postprandial Distress Syndrome: A Phase III Randomized Clinical Trial
por: Sinha, Shubhadeep, et al.
Publicado: (2021) -
A Phase III Prospective Active and Placebo-Controlled Randomized Trial of Vilazodone in the Treatment of Major Depressive Disorder
por: Sinha, Shubhadeep, et al.
Publicado: (2021) -
Profile of acotiamide in the treatment of functional dyspepsia
por: Ueda, Masahiro, et al.
Publicado: (2016) -
Safety, Tolerability, and Immunogenicity of Prescribed Usage of Darbepoetin-Alfa (Hetero Biopharma) in Patients of Chronic Kidney Disease With Renal Anemia: A Post-Marketing Surveillance Study
por: Sinha, Shubhadeep D, et al.
Publicado: (2021) -
Acotiamide and Functional Dyspepsia: A Systematic Review and Meta-Analysis
por: Shrestha, Dhan B, et al.
Publicado: (2021)